Vir Biotechnology, Inc.
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection unde…
Biotechnology
US, San Francisco [HQ]
Cash Flow Statements
7 Sheets · Starting from 2023In Million USD. Margins, Growth Rates In %
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Operating Cash Flow (OCF) | -66.00 | -94.00 | -129.00 | -190.00 | -47.00 | 1,663.00 | -778.00 | |
| Operating Cash (Net) | -66.00 | -94.00 | -129.00 | -190.00 | -47.00 | 1,663.00 | -778.00 | |
| Accounts Receivable | - - | - - | - - | - - | -773.00 | 770.00 | - - | |
| Accounts Payable | 2.00 | 1.00 | - - | - - | - - | - - | - - | |
|
Working Capital
|
- - | - - | - - | - - | - - | - - | - - | |
| Change | 4.00 | 12.00 | 8.00 | 29.00 | -628.00 | 665.00 | -304.00 | |
| Other WC | 2.00 | 11.00 | 7.00 | 30.00 | 92.00 | -105.00 | -304.00 | |
| Investing Activities | ||||||||
| Used Cash (Net) | -29.00 | -60.00 | -256.00 | -9.00 | -140.00 | -1,193.00 | 164.00 | |
| Capital Expenditure | -2.00 | -8.00 | -8.00 | -6.00 | -21.00 | -68.00 | -21.00 | |
| Purchases of Investments | - - | -123.00 | -643.00 | -403.00 | -420.00 | -1,476.00 | -2,016.00 | |
| Sale/Maturity of Investment | - - | 72.00 | 396.00 | 400.00 | 301.00 | 351.00 | 2,202.00 | |
| Property, Plant, Equipment (P&PE) | -2.00 | -8.00 | -8.00 | -6.00 | -21.00 | -68.00 | -21.00 | |
| Acquisitions (Net) | -27.00 | - - | 247.00 | - - | 140.00 | - - | - - | |
| Other Investing Activities | - - | -1.00 | -247.00 | - - | -140.00 | -1,125.00 | 186.00 | |
| Financing Activities | ||||||||
| Used Cash (Net) | -271.00 | -24.00 | -449.00 | -529.00 | -100.00 | -34.00 | -7.00 | |
| Debt Repayment | - - | - - | - - | - - | - - | - - | - - | |
| Dividends Paid | - - | - - | - - | - - | - - | - - | - - | |
|
Common Stock
|
- - | - - | 126 | - - | - - | - - | - - | |
| Issued | - - | - - | 126.00 | 529.00 | 100.00 | 36.00 | 7.00 | |
| Repurchased | - - | - - | - - | - - | - - | - - | - - | |
| Other Financing Activities | 271.00 | 24.00 | 322.00 | - - | 100.00 | 35.00 | - - | |
| Cash Balances | ||||||||
| Begin of Period | 14.00 | 188.00 | 59.00 | 122.00 | 451.00 | 363.00 | 861.00 | |
| End of Period | 188.00 | 59.00 | 122.00 | 451.00 | 363.00 | 867.00 | 254.00 | |
| Change | 174.00 | -129.00 | 63.00 | 328.00 | -88.00 | 504.00 | -606.00 | |
| Non-Cash Balances | ||||||||
| Depreciation and Amortization | - - | 2.00 | 4.00 | 5.00 | 5.00 | 6.00 | 19.00 | |
| Stock Based Compensation | 4.00 | - - | 8.00 | 27.00 | 83.00 | 102.00 | 111.00 | |
| Other | 4.00 | 1.00 | 8.00 | 45.00 | -52.00 | 388.00 | 11.00 | |
| Highlighted metrics | ||||||||
| Free Cash Flow (FCF) | -69.00 | -102.00 | -138.00 | -197.00 | -69.00 | 1,595.00 | -800.00 | |
| Cash Conversion Cycle (CCC) | - - | -23.00 | -14.00 | -6.00 | 271.00 | -16.00 | -54.00 | |
| Invested Capital | - - | - - | - - | - - | - - | - - | - - | |
|
Other Operating Inflows/Outflows
|
||||||||
| Forex Effect on Cash | - - | - - | - - | - - | - - | - - | -7.00 |